Skip to content

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

Menu

Home
ABOUT
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
Access your profile
Login

Menu

Home
ABOUT
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
Access your profile
Login

[denovo_breadcrumbs]

Contemporary treatment approaches to primary immune deficiencies

Questionnaire

To access this module, please register or login:

Login or Register

Contemporary treatment approaches to primary immune deficiencies Contemporary treatment approaches to primary immune deficiencies

Time limit: 0

Questionnaire Summary

0 of 10 Questions completed

Questions:

Information

You have already completed the questionnaire before. Hence you can not start it again.

Questionnaire is loading…

You must sign in or sign up to start the questionnaire.

You must first complete the following:

Results

Questionnaire complete. Results are being recorded.

Results

0 of 10 Questions answered correctly

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Regrettably, you failed to achieve the 70% pass mark required by the accrediting HPCSA.
Please try again!
For queries, please contact cpd@denovomedica.com
Pass
Congratulations on successfully completing our FREE CPD module!
Please click on button just above to download and print your CPD certificate. Alternatively, an email will be sent to you with the link to your profile, there you will find all your CPD certificates to download.
For HPCSA members, please allow 5-10 days for the CPD activity to reflect on your HPCSA profile.

1
2
3
4
5
6
7
8
9
10

Current
Review
Answered
Correct
Incorrect

Question 1 of 10
1. Question
1. The most common symptomatic PIDD is:
A. Agammaglobulinaemia
B. SCID
C. LAD
D. CVID
Question 2 of 10
2. Question
2. IGSC 20% allows for subcutaneous infusion in low volumes, reduces infusion times compared with less concentrated products, and the treatment regimen can be modified to enable treatment individualisation.
A. True
B. False
Question 3 of 10
3. Question
3. A definite diagnosis of a PIDD requires:
A. The presence of ≥4 of 10 warning signs
B. Molecular testing
C. Full blood quantification
D. B and C only
Question 4 of 10
4. Question
4. Patients with a PIDD:
A. Have a significantly increased risk for morbidity and mortality
B. May have typical infections that are atypical in duration and severity
C. May manifest inflammation, autoimmunity and malignancy
D. All of the above
Question 5 of 10
5. Question
5. Initial therapy for the management of a PIDD with humoral immunodeficiency is:
A. Aggressive infection management, IGRT, and antibiotic/antifungal prophylaxis
B. Aggressive infection management and IGRT, but not antibiotic/antifungal prophylaxis
C. IGRT, but not aggressive infection management and antibiotic/antifungal prophylaxis
Question 6 of 10
6. Question
6. IGSC 20% is an IGRT approved for use in PIDD patients aged:
A. Two years and older
B. Six years and older
C. Twelve years and older
D. Eighteen years and older
Question 7 of 10
7. Question
7. When access to molecular diagnostic methodologies is limited, immune system investigations for the neonate suspected of having a PIDD include:
A. Complete blood counts
B. Lymphocyte subset enumeration and immunoglobulin quantification
C. Lymphoproliferative response to mitogens
D. All of the above
Question 8 of 10
8. Question
8. Real-world data regarding the efficacy and tolerability of IGSC 20% for PIDD treatment demonstrated:
A. No treatment-related emergency department visits
B. No treatment discontinuation due to adverse effects
C. Both A and B
D. Neither A nor B
Question 9 of 10
9. Question
9. Secondary causes of hypogammaglobulinaemia include:
A. Certain medications such as methotrexate and benzodiazepines
B. Infectious diseases such as HIV
C. Other systemic disorders such as metabolic syndrome
D. All of the above
Question 10 of 10
10. Question
10. The heterogeneity of PIDD mutations results in diverse phenotypes and severity, making recognition and differential diagnosis difficult.
A. True
B. False

All Rights Reserved 2025 © deNovo Medica (Pty) Ltd in South Africa. The content on this website is intended for healthcare related professionals unless stated otherwise.

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Login

Accessing this module requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?